Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.26
-0.01 (-4.87%)
Bozor ochiq: Aug 12, 2026, 1:40 PM EDT
0.27
-0.00 (-0.78%)
Oldingi bozordan keyin: Aug 11, 2026, 7:54 PM EDT
Vistagen Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, neyropsixiatrik va nevrologik kasalliklar uchun terapiyalarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning mahsulotlar qatori Fasedienolni o'z ichiga oladi, bu ijtimoiy tashvish buzilishi bo'lgan kattalardagi tashvishni davolash uchun III fazali klinik sinovda bo'lgan tadqiqot feromon burun spreyi; va Itruvone, katta depressiv buzilishni davolash uchun IIa fazali klinik sinovda bo'lgan, hidsiz sintetik tadqiqot neyroaktiv feromon burun spreyi. Shuningdek, u menopauza bilan bog'liq issiq bosishlar, premenstrüel disforik buzilish va boshqa ayollar salomatligi bilan bog'liq muammolarni o'z ichiga olgan vazomotor alomatlarni davolash uchun IIa fazali klinik sinovda bo'lgan, hidsiz va ta'msiz sintetik tadqiqot feromon burun spreyi refisolone; ruhiy charchoq buzilishlari keltirib chiqaradigan kognitiv buzilishlarni yaxshilash uchun IIa fazali klinik sinovda bo'lgan tadqiqot feromon burun spreyi PH15; saraton kaxeksiyasi kabi surunkali kasalliklar bilan bog'liq ishtaha yo'qolishini davolash uchun IIa fazali klinik sinovda bo'lgan, hidsiz va ta'msiz sintetik tadqiqot feromon burun spreyi PH284; va depressiya va nevrologik kasalliklarni davolash uchun miyadagi N-metil-D-aspartat retseptoriga ta'sir qiluvchi og'iz orqali yuboriladigan proleyk AV-101ni ishlab chiqadi. Unda ko'plab tashvish bilan bog'liq kasalliklarni ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun AffaMed Therapeutics, Inc. bilan litsenziya va hamkorlik shartnomasi mavjud. Vistagen Therapeutics, Inc. 1998 yilda tashkil etilgan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Integrated Drug Development |
| Dr. Louis Monti M.D., Ph.D. | Senior Vice President of Translational Neuroscience |
| Dr. Mark J. Ginski Ph.D. | Senior VP and Head of Chemistry, Manufacturing & Controls |
| Mr. Joshua S. Prince M.B.A. | Chief Operating Officer |
| Mr. Mark Adrian McPartland | Senior Vice President of Investor Relations |
| Mr. Nick B. Tressler M.B.A. | CFO & Treasurer |
| Mr. Reid G. Adler Esq., J.D. | Chief Legal Officer |
| Mr. Shawn K. Singh J.D. | President, CEO & Director |
| Ms. Elissa Cote | Chief Corporate Development & Strategy Officer |
| Ms. Trisha Fitzmaurice | Senior Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 8-K | vtgn-20260806.htm |
| 2026-08-05 | 8-K | vtgn-20260804.htm |
| 2026-07-31 | DEFA14A | vtgndefa14a-additionalsoli.htm |
| 2026-07-31 | DEF 14A | vtgn-20260731.htm |
| 2026-06-30 | 8-K | vtgn-20260630.htm |
| 2026-06-17 | 8-K | vtgn-20260616.htm |
| 2026-06-15 | 8-K | vtgn-20260615.htm |
| 2026-06-15 | 10-K | vtgn-20260331.htm |
| 2026-06-09 | 8-K | vtgn-20260609.htm |
| 2026-05-19 | 8-K | vtgn-20260518.htm |